At Clinical Labs, we aspire to provide leadership and diagnostic excellence across all of our specialties, and our commitment to oncology is no exception. In addition to leading the industry in traditional molecular analysis with ground-breaking core laboratories, our genetics test centres offer an innovative platform where our pathologists focus their expertise on a comprehensive testing selection dedicated exclusively to oncology.
Inspiring you with trust and confidence, our team will go the extra mile to achieve the best diagnosis for your patients, working together with you to provide the best possible care. Our pathologists are dedicated to continually improving our diagnostic solutions, creating encouraging long-term patient outcomes.
Our RCPA/NATA-accredited Molecular Genetics Labs offer a comprehensive selection of market leading, innovative, accurate and timely cancer screening services – from Somatic Mutation testing in solid tumours to Aspect Liquid Biopsy and beyond.
Somatic Mutation in Solid Tumours
Clinical Labs uses a high-quality genomic analysis, such as Next Generation Sequencing (NGS) testing panels designed to investigate multiple relevant actionable mutations in formalin-fixed paraffin-embedded (FFPE) tumour samples.
The efficiency of NGS of DNA and RNA has led to an increasing number of large, targeted multi-gene somatic mutation panels that provide a more efficient, cost- and tissue-saving tumour analysis. They confer greater depth of coverage in selected areas of interest (e.g., hotspot regions with known actionable mutations, rarer mutations and tumour sub-clones), faster turnaround, and more clinically relevant data.
At Clinical Labs we currently offer Somatic Mutation testing for the below cancers (click the links for detailed information):
Download Somatic Mutation Brochure
Download Somatic Mutation Request Form Download Somatic Mutation Request Form - WA
Aspect Liquid Biopsy: Circulating Tumour DNA (ctDNA) Testing in Plasma
Aspect Liquid Biopsy is a new, non-invasive, safe and ultrasensitive cancer screening option which identifies genomic alterations from a simple blood test using the circulating tumour DNA (ctDNA). Clinical Labs is proud to be the first Australian private laboratory to offer liquid biopsy, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure.
At Clinical Labs we currently offer Aspect Liquid Biopsy testing for the below cancers (click the links for detailed information):
Benefits of liquid biopsy:
- Liquid biopsy is less invasive
- Liquid biopsy can identify therapeutic targets
- ctDNA shows high concordance with solid tissue biopsies
- ctDNA is a highly specific real time monitoring biomarker
- ctDNA reflects the overall tumour information
- ctDNA detects early relapse
- Liquid biopsy is the quality choice for monitoring tumour burden and therapeutic response
- ctDNA detects minimal residual disease (MRD)
Watch our two educational modules on Aspect Liquid Biopsy, presented by the National Director of Molecular Genetics at Australian Clinical Labs, Associate Professor Mirette Saad.
Aspect Liquid Biopsy | Educational Module | Part 1 | Approx 17 mins
Aspect Liquid Biopsy | Educational Module | Part 2 | Approx 18 mins
Download Aspect Liquid Biopsy Doctor BrochureDownload Aspect Liquid Biopsy Patient Brochure
Download Aspect Liquid Biopsy Request Form
EndoPredict® for Breast Cancer
- PARTIAL MEDICARE REBATE COMING SOON -
EndoPredict® for Breast Cancer is an in vitro multi-gene diagnostic test that provides highly important and clear information for different stages of treatment planning for patients with estrogen receptor positive, HER2-negative, primary breast cancer.
It helps to define the risk of breast cancer recurrence, the benefits of chemotherapy and who can benefit from extended endocrine therapy.
EndoPredict at a Glance
- Only prognostic test that can answer
- whether your patient can safely avoid chemotherapy
- how beneficial chemotherapy would be
- whether your patient can avoid extended endocrine therapy - Largest “true” low risk group for safe reduction of chemotherapy
- more than 70% of N0 patients
- up to 30% of N+ patients - Second generation gene expression test for superior prognostic power
- Unique gene selection for accurate early and late risk assessment
- Consistent study cohorts and constant cut-off
- Clear low- and high-risk category
- Rapid results
Download EndoPredict Summary BrochureDownload EndoPredict Expanded Brochure
Download EndoPredict Request FormDownload EndoPredict Request Form (WA)
For more information on molecular testing options for breast cancer click on the below link.
The content on our Molecular Cancer Services page is written by Associate Professor Mirette Saad, National Director of Molecular Genetics at Australian Clinical Labs.
 |
Assoc. Prof. Mirette SaadMBBS (Hons), MD, MAACB, FRCPA, PhD |
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer.
Back to Molecular Cancer Services Homepage